Effects of bilirubin on perioperative myocardial infarction and its long-term prognosis in patients undergoing percutaneous coronary intervention

Table 4 Association between serum total bilirubin and clinical outcomes

Events	Tertile I	Tertile II	Tertile III
Composite MACE1
Number events/participants	118 (23.2)	81 (19.6)	59 (15.3)
Adjust HR and 95%CI	1.0 (ref)	0.837 (0.627, 1.119)	0.667 (0.485, 0.918)a
Cardiac death
Number events/participants	27 (5.3)	13 (3.1)	13 (3.4)
Adjust HR and 95%CI	1.0 (ref)	0.546 (0.28, 1.065)	0.588 (0.295, 1.171)
Non-fatal myocardial infarction
Number events/participants	13 (2.6)	11 (2.7)	7 (1.8)
Adjust HR and 95%CI	1.0 (ref)	1.113 (0.487, 2.547)	0.736 (0.286, 1.898)
Non-fatal stroke
Number events/participants	2 (0.4)	2(0.5)	2 (0.5)
Adjust HR and 95%CI	1.0 (ref)	1.534 (0.213, 11.067)	1.888 (0.251, 14.211)
Revascularization2
Number events/participants	84 (16.5)	59 (14.3)	39 (10.1)
Adjust HR and 95%CI	1.0 (ref)	0.814 (0.608, 1.089)	0.633 (0.458, 0.875)a

¹Major cardiovascular adverse event was defined as a composite of cardiac death, myocardial infarction, stroke and revascularization.

²Adjusted model included age, diabetes, unstable angina, LDL-C and numbers of stents implanted.

^aP < 0.05.

CI: Confidence intervals; HR: Hazard ratio; MACE: Major cardiovascular adverse events.